Reneo Pharma Q1 net loss $15.1M; STRIDE enrollment complete, topline 4Q23

OnKure Therapeutics, Inc.

2023-Q1 EPS reported -$0.60

Net loss of $15.1M ($0.60/sh) vs $13.0M ($0.53) in Q1 2022.
Cash, equivalents, and short-term investments totaled $93.8M as of March 31, 2023.
Completed enrollment of pivotal STRIDE study (213 patients); topline results expected Q4 2023.
Raised $68.3M gross from public offering and private placement in May 2023.
Received FDA Fast Track designation for mavodelpar in long-chain fatty acid oxidation disorder.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OnKure Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $15.1 million, EPS $0.60 per share.

Period: the quarter ended March 31, 2023
Net income: net loss of $15.1 million
EPS: $0.60 per share
Result: reported results

Exact text from the filing

We reported a net loss of $15.1 million, or $0.60 per share, during the first quarter of 2023, compared to a net loss of $13.0 million, or $0.53 per share, for the same period in 2022.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.